4D Molecular Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $85.2M | $37.0K | $20.7M | $3.1M | $18.0M | $13.6M | $7.0M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | — | — | — | — | — | — |
| SG&A Expense | $49.1M | $46.6M | $36.5M | $32.9M | $28.0M | $17.2M | $13.9M |
| Operating Income | $-159.5M | $-187.8M | $-112.9M | $-110.0M | $-71.3M | $-56.7M | $-50.8M |
| Operating Margin | -187.2% | -507,678.4% | -544.6% | -3,516.5% | -395.5% | -416.3% | -726.7% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | $-140.1M | $-160.9M | $-100.8M | $-107.5M | $-71.3M | $-56.7M | $-49.3M |
| Net Margin | -164.4% | -434,778.4% | -486.6% | -3,435.4% | -395.4% | -416.5% | -705.8% |
| EPS (Basic) | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 | $-8.82 | $-9.59 |
| EPS (Diluted) | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 | $-8.82 | $-9.59 |
| Shares Outstanding (Basic) | 57.9M | 53.9M | 39.1M | 32.4M | 27.7M | 26.7M | 5.2M |
| Shares Outstanding (Diluted) | 57.9M | 53.9M | 39.1M | 32.4M | 27.7M | 26.7M | 5.2M |
| Dividends Per Share | — | — | — | — | — | — | — |